Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.57 |
| ▸ | QDPR | P09417 | 3/20 | 0.55 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
| ▸ | KHK | P50053 | 3/20 | 0.44 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.42 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16422718 | 0.98 | HTR2C (0.58) | HTR2CQDPRSIGMAR1NISCHHTR2A | |
| SCHEMBL4670817 | 0.87 | SIGMAR1 (0.57) | HTR2CQDPRSIGMAR1HTR2AHTR7 | |
| SCHEMBL3383939 | 0.85 | HTR2C (0.62) | HTR2CQDPRSIGMAR1HTR2AHTR7 | |
| SCHEMBL14956908 | 0.85 | QDPR (0.60) | HTR2CQDPRSIGMAR1HTR7HTR6 | |
| Hydrochloric Acid SCHEMBL6371753 | 0.83 | HTR2C (0.64) | HTR2CQDPRSIGMAR1HTR2AHTR7 | |
| SCHEMBL24669951 | 0.81 | HTR2C (0.57) | HTR2CQDPRSIGMAR1KHK | |
| SCHEMBL27866836 | 0.81 | QDPR (0.73) | HTR2CQDPRSIGMAR1KHK | |
| SCHEMBL904201 | 0.81 | HTR2C (0.49) | HTR2CQDPRSIGMAR1HTR2AHTR7 | |
| SCHEMBL16874849 | 0.80 | QDPR (0.66) | HTR2CQDPRSIGMAR1TGFBR1ACVR1 | |
| Hydrochloric Acid SCHEMBL979625 | 0.79 | QDPR (0.64) | HTR2CQDPRSIGMAR1TGFBR1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118084916-A | Tri-heterocyclic compounds and uses thereof | 成都赜灵生物医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-9403798-B2 | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-9403798-B2 | Triazinone compound and T-type calcium channel inhibitor | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL CORPORATION (JP) | 2015-03-05 | — | — | US | disclosed |
| EP-2832728-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | Nissan Chemical Industries, Ltd. (JP) | 2015-02-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150065705-A1 | TRIAZINONE COMPOUND AND T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1E, CACNA1I, CACNA1G | HTR2C 308/4885QDPR 1209/4885SIGMAR1 624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.